株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

退形成性乏突起膠腫:パイプライン製品の分析

Anaplastic Oligoastrocytoma - Pipeline Review, H2 2019

発行 Global Markets Direct 商品コード 361616
出版日 ページ情報 英文 87 Pages
即納可能
価格
本日の銀行送金レート: 1USD=108.53円で換算しております。
退形成性乏突起膠腫:パイプライン製品の分析 Anaplastic Oligoastrocytoma - Pipeline Review, H2 2019
出版日: 2019年12月27日 ページ情報: 英文 87 Pages
概要

当レポートでは、退形成性乏突起膠腫に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

退形成性乏突起膠腫の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

退形成性乏突起膠腫:企業で開発中の治療薬

退形成性乏突起膠腫:大学/機関で研究中の治療薬

退形成性乏突起膠腫:パイプライン製品の概況

  • 臨床段階の製品

退形成性乏突起膠腫:企業で開発中の製品

退形成性乏突起膠腫:大学/機関で研究中の製品

退形成性乏突起膠腫の治療薬開発に従事している企業

  • Axelar AB
  • Cavion LLC
  • Celldex Therapeutics, Inc.
  • e-Therapeutics Plc
  • Novartis AG
  • Pfizer Inc.

退形成性乏突起膠腫:治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

退形成性乏突起膠腫:最近のパイプライン動向

退形成性乏突起膠腫:休止中のプロジェクト

付録

図表

List of Tables

  • Number of Products under Development for Anaplastic Oligoastrocytoma, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Anaplastic Oligoastrocytoma - Pipeline by Astellas Pharma Inc, H2 2019
  • Anaplastic Oligoastrocytoma - Pipeline by Bayer AG, H2 2019
  • Anaplastic Oligoastrocytoma - Pipeline by Boehringer Ingelheim International GmbH, H2 2019
  • Anaplastic Oligoastrocytoma - Pipeline by Novartis AG, H2 2019
  • Anaplastic Oligoastrocytoma - Pipeline by Pfizer Inc, H2 2019
  • Anaplastic Oligoastrocytoma - Pipeline by TheraBiologics Inc, H2 2019
  • Anaplastic Oligoastrocytoma - Dormant Projects, H2 2019
  • Anaplastic Oligoastrocytoma - Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development for Anaplastic Oligoastrocytoma, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products by Top 10 Targets, H2 2019
  • Number of Products by Stage and Top 10 Targets, H2 2019
  • Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
目次
Product Code: GMDHC11740IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anaplastic Oligoastrocytoma - Pipeline Review, H2 2019, provides an overview of the Anaplastic Oligoastrocytoma (Oncology) pipeline landscape.

Anaplastic oligoastrocytoma is a brain tumor that forms when two types of cells in the brain, called oligodendrocytes and astrocytes, rapidly increase in number to form a mass. These brain cells are known as glial cells, which normally protect and support nerve cells in the brain. Symptoms include seizures, headaches, and personality changes. Other symptoms vary by location and size of the tumor. Treatment includes chemotherapy and surgery.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anaplastic Oligoastrocytoma - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Anaplastic Oligoastrocytoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anaplastic Oligoastrocytoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Anaplastic Oligoastrocytoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Phase I stages are 4 and 3 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Anaplastic Oligoastrocytoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Anaplastic Oligoastrocytoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Anaplastic Oligoastrocytoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Anaplastic Oligoastrocytoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Anaplastic Oligoastrocytoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Anaplastic Oligoastrocytoma (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Anaplastic Oligoastrocytoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Anaplastic Oligoastrocytoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Anaplastic Oligoastrocytoma - Overview
    • Anaplastic Oligoastrocytoma - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Anaplastic Oligoastrocytoma - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Anaplastic Oligoastrocytoma - Companies Involved in Therapeutics Development
    • Astellas Pharma Inc
    • Bayer AG
    • Boehringer Ingelheim International GmbH
    • Novartis AG
    • Pfizer Inc
    • TheraBiologics Inc
  • Anaplastic Oligoastrocytoma - Drug Profiles
  • Anaplastic Oligoastrocytoma - Dormant Projects
  • Anaplastic Oligoastrocytoma - Discontinued Products
  • Anaplastic Oligoastrocytoma - Product Development Milestones
  • Appendix